Mutations in the Cardiac Ryanodine Receptor Gene (hRyR2) Underlie Catecholaminergic Polymorphic Ventricular Tachycardia

SG Priori, C Napolitano, N Tiso, M Memmi, G Vignati… - Circulation, 2001 - Am Heart Assoc
SG Priori, C Napolitano, N Tiso, M Memmi, G Vignati, R Bloise, V Sorrentino, GA Danieli
Circulation, 2001Am Heart Assoc
Background—Catecholaminergic polymorphic ventricular tachycardia is a genetic
arrhythmogenic disorder characterized by stress-induced, bidirectional ventricular
tachycardia that may degenerate into cardiac arrest and cause sudden death. The
electrocardiographic pattern of this ventricular tachycardia closely resembles the
arrhythmias associated with calcium overload and the delayed afterdepolarizations
observed during digitalis toxicity. We speculated that a genetically determined abnormality …
Background—Catecholaminergic polymorphic ventricular tachycardia is a genetic arrhythmogenic disorder characterized by stress-induced, bidirectional ventricular tachycardia that may degenerate into cardiac arrest and cause sudden death. The electrocardiographic pattern of this ventricular tachycardia closely resembles the arrhythmias associated with calcium overload and the delayed afterdepolarizations observed during digitalis toxicity. We speculated that a genetically determined abnormality of intracellular calcium handling might be the substrate of the disease; therefore, we considered the human cardiac ryanodine receptor gene (hRyR2) a likely candidate for this genetically transmitted arrhythmic disorder.
Methods and Results—Twelve patients presenting with typical catecholaminergic polymorphic ventricular tachycardia in the absence of structural heart abnormalities were identified. DNA was extracted from peripheral blood lymphocytes, and single-strand conformation polymorphism analysis was performed on polymerase chain reaction–amplified exons of the hRyR2 gene. Four single nucleotide substitutions leading to missense mutations were identified in 4 probands affected by the disease. Genetic analysis of the asymptomatic parents revealed that 3 probands carried de novo mutations. In 1 case, the identical twin of the proband died suddenly after having suffered syncopal episodes. The fourth mutation was identified in the proband, in 4 clinically affected family members, and in none of 3 nonaffected family members in a kindred with 2 sudden deaths that occurred at 16 and 14 years, respectively, in the sisters of the proband.
Conclusions—We demonstrated that, in agreement with our hypothesis, hRyR2 is a gene responsible for catecholaminergic polymorphic ventricular tachycardia.
Am Heart Assoc